Excess visceral fat, rather than BMI alone, is a key driver of cardiovascular risk in people with HIV receiving antiretroviral therapy. The study authors presented their findings at the Conference on...
In a presentation at the Practical Updates in Primary Care 2025 virtual conference, Angela Fitch, MD, FACP, MFOMA, Dipl ABOM, detailed the role primary care physicians play in obesity care and provided an...
At the Practical Updates in Primary Care 2025 conference, Julianne Blythe, MPA, PA-C, RPSGT, outlined practical strategies for identifying and managing obstructive sleep apnea, emphasizing screening tools,...
A study presented at the American College of Cardiology's 74th Annual Scientific Session found that GLP-1RA use in patients with psoriasis was linked to a lower incidence of major adverse cardiovascular...
A new study reveals that most patients discontinue GLP-1 receptor agonists within a year, with significantly higher dropout rates among those using them for weight loss rather than diabetes management.
...
In a recent randomized, double-blind, placebo-controlled study, researchers found reductions in both body weight and knee pain in individuals with obesity and knee osteoarthritis following weekly treatment...
Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
